# A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

> **NCT05576298** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** Insulin degludec injection, RD15003
- **BIOLOGICAL:** Insulin degludec, Tresiba

## Key facts

- **NCT ID:** NCT05576298
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576298, "A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05576298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*